Kwame Zaire stands at the intersection of high-stakes manufacturing and the digital frontier. With an extensive background in electronics, equipment management, and production safety, he has become a leading voice on how predictive technologies can transform the factory floor. As the industry moves through 2026, Zaire’s focus is on bridging the gap between the theoretical promise of artificial intelligence and the practical, often messy reality of biologics production. His insights offer a grounded perspective for organizations trying to navigate the shift from manual processes to fully integrated, intelligent systems.
This conversation explores the fundamental hurdles that continue to prevent AI from scaling effectively within biopharmaceutical manufacturing. We discuss the inherent friction within multi-party relationships between sponsors and contract manufacturers, the critical distinction between sheer data volume and meaningful data context, and the high-stakes “translation” errors that occur during technology transfers. Furthermore, we examine the strategic rollout of digital twins, the necessity of a standardized maturity index to evaluate readiness, and how human accountability remains the cornerstone of regulatory compliance in an increasingly automated world.
Biopharmaceutical production frequently involves a vast, complex network of sponsors and CDMOs that use different systems to manage information. How does this fragmented landscape create a bottleneck for companies attempting to implement AI at scale?
The reality is that biologics manufacturing is inherently a team sport, but unfortunately, everyone is playing by a different set of rules. When a sponsor pharma company works to get a drug to market, they aren’t just using one facility; they are tapping into a wide-reaching network of manufacturers and testing sites across the globe. This results in data being spread thin across different organizations, each with its own legacy software and proprietary methods for recording results. You might have ten different sites recording the same process parameters, but because they are titled differently or stored in incompatible formats, the AI simply can’t find the patterns it needs to learn. It’s incredibly frustrating for a production manager to have the best AI tools in the world sitting idle because the data isn’t “cleaned up” enough to be used repeatedly. Without a unified way to look at this information, the excitement around digital transformation often hits a brick wall before the first model is even deployed.
There is a common misconception that simply having more data is the key to AI success, yet your focus is often on the quality and context of that data. Why is a “data lake” insufficient if it lacks the proper infrastructure and contextual tagging?
I often see manufacturers falling into the trap of thinking that a bigger database is always better, but volume without context is just noise. If you’re looking at a measurement for pH or conductivity, that number tells you almost nothing unless you know exactly where it originated in the process, which specific piece of equipment was used, and the precise moment the sample was taken. When we try to compare a small-scale purification process in a lab to a massive commercial-scale run, the complexities multiply instantly. Without those contextual tags, you aren’t comparing apples to apples; you’re trying to find a signal in a chaotic mess of variables. To make AI work, the information must be easily and simply accessible so that anyone in the organization can export it and get the same result every single time. It’s about building a foundation where the data can actually speak for itself, rather than requiring a team of engineers to explain what a specific column in a spreadsheet actually means.
The transition of a drug substance from development into clinical and commercial production is a high-stakes moment. How do the different “data languages” used by various organizations lead to failures during this technology transfer?
This is where the friction in the industry becomes most visible and, frankly, most expensive. Every organization has its own internal data language—or at least a distinct dialect—and when you try to move a program from a sponsor to a CDMO, things often get lost in translation. We see situations where a liaison has to act as a manual translator, literally rewriting and interpreting data from one system to another to ensure consistency. If there is a single transcription error or a misunderstanding of a process parameter during this exchange, the consequences are immediate and severe. We’ve seen engineering batches and clinical batches—the very ones intended for Phase 1 or Phase 2 trials—fail completely because of these simple data-sharing mistakes. Having to go back and remanufacture a substance because of a translation error isn’t just a technical setback; it’s a massive waste of resources and time that could have been avoided with a more standardized, federated approach to data integration.
Digital twins are often discussed as a “holy grail” for manufacturing, yet the 2026–2029 outlook suggests they are still largely in the pilot stages. What is a more practical starting point for facilities that want to move beyond the experimental phase with this technology?
I’ve always been a bit skeptical of the idea that we can just flip a switch and have a digital twin that mimics an entire, end-to-end biomanufacturing process overnight. The infrastructure just isn’t there yet to connect every operation and site into one seamless model. Instead, the most successful companies are focusing on individualized digital twins that target specific, high-value unit operations. By perfecting a twin for a single purification step or a specific bioreactor setup, you build a “working” model that provides real value without the overwhelming complexity of a full-plant simulation. Once these smaller twins are performing reliably, we can start stitching them together into a more comprehensive system. I fully expect that advanced CDMOs will lead the way by incorporating these modular twins into the design of their new facilities, but we have to walk before we can run.
To bridge the gap between AI ambition and actual readiness, the Biomanufacturing AI Maturity Index (BAMI) provides a six-level framework for evaluation. How can this index help a manufacturer realize they might be trying to implement AI before their governance is actually ready?
The BAMI framework is essential because it forces an organization to take a hard look in the mirror before they spend millions on a technology they can’t support. Many companies are eager to jump into advanced AI applications, but the index often reveals that their digital maturity or their governance structures are still in their infancy. You cannot have a model influencing regulated, GMP decisions if you don’t have a mature system for validation, change control, and data integrity already in place. The framework evaluates both the internal digital operations and the ability to share data across organizational boundaries, identifying where the gaps are. It prevents the costly “rework” that happens when a company implements an AI tool only to realize later that it doesn’t meet compliance standards. It’s about ensuring the foundation is solid enough to hold the weight of the innovation you’re trying to build on top of it.
There was an initial concern that regulators might resist the introduction of AI in highly controlled environments. Now that we see more openness from these bodies, what remains the primary expectation for human accountability in a GMP setting?
I was pleasantly surprised to see how open regulators have become to AI, but that openness comes with a very clear set of strings attached. The expectation is that while the tools change, the underlying principles of safety and efficacy remain exactly the same. We still need rigorous validation and a clear audit trail for every decision made on the factory floor. Most importantly, the industry must recognize that the humans behind these tools are still the ones who are ultimately accountable. AI can provide the monitoring and the advisory insights, but the final responsibility to apply those tools in an appropriate, ethical, and safe way rests with the operators and the quality teams. Regulators want to see that we aren’t just blindly following an algorithm, but rather using it as a sophisticated tool to enhance our existing, proven frameworks of data integrity.
What is your forecast for the integration of AI across the biomanufacturing landscape over the next few years?
I fully anticipate we will see AI tools being applied to nearly every single part of the manufacturing process, from initial development analytics to real-time process control. However, this isn’t going to be a revolution that happens overnight; it’s going to be a gradual, steady evolution driven by our own digital maturity. The speed of adoption will depend entirely on how quickly we can stabilize our data foundations—not just within our own four walls, but across our entire network of partners. As those connections between sponsors and CDMOs grow stronger and more standardized, the ability for AI to scale will accelerate. We are moving toward a future where “data language” barriers are a thing of the past, allowing us to focus entirely on the science of making life-saving medicines more efficiently than ever before.
